Dacarbazine (DTIC) is a cytotoxic drug widely used for melanoma treatment. However, the putative contribution of anticancer immune responses in the efficacy of DTIC has not been evaluated. By testing how DTIC affects host immune responses to cancer in a mouse model of melanoma, we unexpectedly found that both natural killer (NK) and CD8 þ T cells were indispensable for DTIC therapeutic effect. Although DTIC did not directly affect immune cells, it triggered the upregulation of NKG2D ligands on tumor cells, leading to NK cell activation and IFNg secretion in mice and humans. NK cell-derived IFNg subsequently favored upregulation of major histocompatibility complex class I molecules on tumor cells, rendering them sensitive to cytotoxic CD8 þ T cells. Accordingly, DTIC markedly enhanced cytotoxic T lymphocyte antigen 4 inhibition efficacy in vivo in an NK-dependent manner. These results underscore the immunogenic properties of DTIC and provide a rationale to combine DTIC with immunotherapeutic agents that relieve immunosuppression in vivo.
INTRODUCTION
Beyond their cytotoxicity on tumor cells, some anticancer agents promote the activation of the host immune system, which can make a decisive contribution to therapeutic success Zitvogel et al., 2008) . Drugs such as cyclosphosphamide and 5-fluorouracil were indeed, respectively, shown to selectively deplete regulatory T cells (Tregs) (Ghiringhelli et al., 2004) and myeloid-derived suppressor cells (MDSCs) (Vincent et al., 2010; Apetoh et al., 2011) in vivo, resulting in enhanced antitumor responses. In addition, anthracyclines, oxaliplatin, and radiotherapy induce immunogenic cell death, leading to the activation of T cell-based anticancer immune responses (Apetoh et al., 2007; Obeid et al., 2007; Ghiringhelli et al., 2009) . Platinum derivates were also shown to stimulate the expression of ligands for NKG2D, an natural killer (NK) cell-activating receptor, which determines the innate immune response against leukemic tumors (Gasser et al., 2005) . NKG2D recognition by NK cells may be a preponderant mechanism in some cancers, including melanoma (Pende et al., 2001) , and regulation of NKG2D ligand expression by tumor cells affects NK cell cytotoxicity (Pietra et al., 2012) . Many different NKG2D ligands have been described to be differentially expressed between models, namely Rae-1, Mult-1, and H-60 in mice, and MICA, MICB and ULBPs in human cells. These ligands are activators of NK cell functions when membrane bound (Sutherland et al., 2006; Champsaur and Lanier, 2010) , but may also inhibit immunity in their soluble form (Salih et al., 2008; Paschen et al., 2009) .
Dacarbazine (DTIC) is an alkylating agent approved to treat metastatic melanoma in humans. This has been administered as a first-line treatment for metastatic melanoma since the 1970s (Gerner et al., 1975) and is still used as such when mutant BRaf-targeting therapy is not applicable. However, response rates to this treatment remain poor (Lui et al., 2007) . Although the direct cytotoxic activity of DTIC has been known for long, little information is currently available about DTIC immunomodulatory effects. To address how DTIC affects anticancer immune responses, we evaluated the contribution of innate and adaptive immune cells in the anticancer effects of DTIC in a mouse melanoma model. We found that NK and CD8 þ T cells were both required for DTIC antitumor activity. DTIC induced upregulation of NKG2D ligands on B16 melanoma cells and human melanoma cells, leading to NK cell activation. Activated NK cells produced IFNg, which enhanced major histocompatibility complex I (MHC-I) tumor cell expression, resulting in the activation of antitumorspecific CD8 þ T cells in vitro and in vivo. Furthermore, a combination of DTIC with cytotoxic T lymphocyte antigen 4 (CTLA4) blockade also has an NK-dependent antitumor effect. These results underscore the immunogenic properties of DTIC that rely on its ability to induce NKG2D ligand expression on tumor cells.
RESULTS
DTIC exerts an antitumor effect in a CD8-, IFNc-, and NK-dependent manner
We first treated wild-type or nude mice bearing a subcutaneous B16F10 melanoma tumor with DTIC. This treatment delayed tumor growth in wild-type mice but had no effect on tumor progression in nude mice, suggesting that the DTIC antitumor effect depends on T cells (Figure 1a) .
To further delineate the contribution of the host immune response to the anticancer effect of DTIC, we treated tumorbearing mice with DTIC along with isotype or depleting anti-CD8, CD4, IFNg, or NK1.1 antibodies to eliminate, respectively, CD8
þ T cells (Figure 1b ), CD4 þ T cells (Figure 1c ), IFNg (Figure 1d ), or NK cells (Figure 1e ). Although CD4 þ T cells were dispensable for DTIC therapeutic efficacy, we found that the DTIC antitumor effect relied on CD8 þ T cells, IFNg, and NK cells. Interestingly, in NK-and IFNg-depleted mice, the DTIC effect was totally abrogated, whereas in CD8 þ T cell-depleted mice DTIC only exerted an early and transient effect on tumor progression, suggesting that NK cells and IFNg, which act as early effectors against tumor progression, might subsequently trigger CD8 þ T-cell activation. To further assess the immune-based effect of DTIC, we inoculated mice with 10 less B16F10 cells than usual and treated them according to the standard protocol. We observed that in mice in which the low-dose tumor was implanted, the DTIC was more effective, suggesting a nontumor-based phenomenon ( Figure 1f) .
Taken together, these data underscore the contribution of CD8 þ T cells, IFNg, and NK cells in the anticancer activity of DTIC.
DTIC does not directly affect immune effectors
Chemotherapy could harness the host immune system by eliminating immunosuppressive cells such as Tregs and MDSCs (Ghiringhelli et al., 2004; Suzuki et al., 2005; Vincent et al., 2010) , by inducing dendritic cell (DC) maturation (Tanaka et al., 2009) or by eliciting ''immunogenic cell death'' of tumor cells, which has been shown to rely on the expression of cell surface calreticulin (Obeid et al., 2007) . To address these possibilities, we have first evaluated the frequency of Tregs and MDSCs in the spleen of DTIC-treated tumor-bearing mice and found that DTIC did not significantly alter the frequency of these immunosuppressive cells (Figure 2a and b) .
We then assessed whether DTIC promoted the maturation of antigen-presenting cells by testing the effect of a single systemic injection of DTIC or lipopolysaccharide on the maturation pattern of splenic DCs. Although lipopolysaccharide induced a massive upregulation of CD86 and CD40, DTIC administration did not affect the expression of these markers, ruling out DTIC involvement in DC maturation (Figure 2c ).
We next tested the ability of DTIC to trigger an immunogenic form of cell death by monitoring the expression of cell surface calreticulin on B16 cells. Unlike doxorubicin, which is known to trigger calreticulin cell surface expression (Obeid et al., 2007) , DTIC treatment could not trigger calreticulin membrane expression on B16 cells (Figure 2d ), suggesting that the antitumor effects of DTIC cannot be explained by its ability to trigger an immunogenic form of tumor cell death. Finally, we found that DTIC injection did not modify the number of total CD4, CD8, CD19, CD11c, or NK cells in lymphoid organs of tumor-bearing mice (not shown). Nevertheless, we noted NK and CD8 þ T-cell activation assessed by CD69 ( Figure 2e ) and NKG2D ( Figure 2f ) labeling in tumordraining lymph nodes after DTIC injection. In vitro, DTIC did not affect NK or CD8 T-cell phenotype (not shown).
Altogether, these data suggest that although the antitumor effect of DTIC is dependent on CD8 þ T and NK cells, DTIC did not affect Tregs, MDSC, and DC maturation, and failed to induce immunogenic death of tumor cells. In contrast, DTIC induced local activation of NK and CD8 þ T cells, suggesting that the DTIC-mediated NK and CD8 þ T-cell activation is indirect.
DTIC induces the expression of NKG2D ligands and induces NK cell activation
Previous reports have shown that chemotherapy-induced cell stress triggers the expression of NKG2D ligands on leukemic cell lines, leading to NK cell activation (Fine et al., 2010; Nice et al., 2010) . As our results showed NK cell activation following DTIC treatment in vivo, we tested whether DTIC induced NKG2D ligand expression in melanoma cells. We found that DTIC induced Rae1 and Mult1 gene expression in B16 cells (Figure 3a ). This increased NKG2D ligand expression resulted in detection of membrane Rae-1 and Mult-1 proteins, as well as total NKG2D ligands, on B16F10 tumor cells 24 hours following DTIC treatment (Figure 3b ), whereas, according to the literature, we failed to detect any of them in phosphate-buffered saline (PBS)-treated B16F10 (Zhang and Sentman, 2011 ). Thereafter, we tested NK cell cytotoxicity against B16 cells after DTIC treatment. We observed that DTIC enhances NK cell toxicity ( Figure 3c ). In addition, we could demonstrate that coculture of NK cells with B16 cells treated with DTIC induced a production of IFNg ( Figure 3d ). We further observed that the lysis of DTIC-treated B16 cells by NK cells was dependent on perforin/granzyme B but not TRAIL, as shown by the use of concanamycin A or blocking anti-TRAIL antibody ( Figure 3e ). Importantly, by using a blocking NKG2D-Fc, we could observe that NKG2D engagement was mandatory for both NK cell cytotoxic effects ( Figure 3f ) and IFNg secretion ( Figure 3g ) when using DTICtreated B16 cells. Finally, we tested the dependency of DTIC treatment efficacy in vivo. We treated melanoma-bearing mice with DTIC along with isotype or depleting anti-NKG2D. We observed that NKG2D blockade hinders the DTIC effect on tumor growth (Figure 3h ).
To generalize our in vitro and animal results, we took advantage of a human melanoma cell line MelC (Fregni et al., 2011) . To check whether DTIC treatment induces upregulation of NKG2D ligands in MelC cells, we analyzed transcripts for MICA, MICB, ULBP1, ULPB2, and ULPB3 in MelC cells treated or not treated with DTIC (Figure 4a ). MICA and MICB were significantly upregulated upon DTIC exposure, whereas the other NKG2D ligands showed a slight increase in expression. In accordance with these results, we also detected the presence of MICA and MICB proteins in MelC cells by flow cytometry (Figure 4b ). To test the functional relevance of this observation, we performed coculture of human NK cells with PBS-or DTIC-treated MelC cells. DTIC treatment efficiently sensitizes the melanoma target to NK cell lysis, indicating the validity of our hypothesis in human settings (Figure 4c ). We also noted that this increase in target mortality was prevented by a blocking anti-human NKG2D antibody (Figure 4d ). We confirmed this observation in other human melanoma cell lines. We found that three out of five tested melanoma cell lines are prone to NKG2D ligand upregulation-dependent NK lysis induced by DTIC (data not shown).
Altogether, these data demonstrate that DTIC-induced NKG2D ligand upregulation on tumor cells leads to NK cell activation.
DTIC-driven production of IFNc by NK cells triggers upregulation of MHC-I and favors tumor cell killing by CTL
B16 cells poorly express MHC-I molecules at steady state, and this phenomenon impedes their recognition by CD8 þ T cells (Zoller et al., 1988; Lugade et al., 2008) . We observed that the supernatant of NK cells cocultured with DTIC-treated B16 cells induced the expression of MHC-I molecules on fresh B16 cells. This MHC-I upregulation was entirely due to IFNg, as IFNg blockade aborted the phenomenon (Figure 5a ). By using B16 cells expressing ovalbumin (OVA) antigen (B16OVA), we showed that, although PBS-treated B16OVA express low levels of MHC-I as expected (Lugade et al., 2008) , the supernatant of NK cells cocultured with DTICtreated tumor cells induced the expression of OVA peptide (SIINFEKL)-MHC-I complex on tumor cell surface in an IFNgdependent manner, indicating enhanced endogenous tumor antigen presentation (Figure 5b ). We hypothesized that this increased availability of peptide/MHC-I complexes may enhance B16OVA susceptibility to antigen-specific cytotoxic T cells. We took advantage of OT-I transgenic mice, in which CD8 þ T cells bear an OVA-specific TCR. In vitro, pretreatment of B16OVA cells with the supernatant of NK cells cocultured with DTIC-treated tumor cells enhances their killing by OT-I CD8 þ T cells (Figure 5c ). To test the in vivo relevance of this observation, we treated mice bearing B16OVA tumors with DTIC, and then injected them with carboxyfluorescein succinimidyl ester (CFSE)-labeled OT-I cells and monitored their outcome. We found that DTIC treatment induced higher OT-I proliferation in tumordraining lymph nodes compared with control. This effect is blunted by IFNg neutralization or NK cell depletion, suggesting that DTIC-driven OT-I in vivo activation was dependent on NK cell activation (Figure 5d ).
Altogether, these data indicate that, in vivo and in vitro, IFNg produced by NK cells after DTIC treatment enhances tumor cell capacity to present tumor antigens on MHC-I and favors CD8
þ T-cell activation.
CTLA4 blockade þ DTIC synergy relies on NK cells
Given that our previous experiments indicate the NK cell dependency of the DTIC treatment, we questioned whether NK cells are mandatory for efficacy of DTIC-based combined chemotherapeutic regimen. Recently, treatment inhibiting CTLA4, an inhibitor of T cell-based cytotoxicity (Walker and Sansom, 2011) , has proven beneficial in combination with DTIC (Robert et al., 2011) . We decided to test CTLA4 þ DTIC inhibition in our experimental model, with or without NK depletion. As expected from the literature (van Elsas et al.,
1999; Dranoff, 2011) , the effect of anti-CTLA4 treatment alone on tumor growth is comparable to that of DTIC alone, and the anti-CTLA4 þ DTIC combination gives better antitumor efficacy ( Figure 6a ). As already seen in Figure 1 , DTIC efficacy is totally blunted in mice depleted of NK cells; furthermore, NK cell depletion abrogated not only the antitumor effect of anti-CTLA4 alone but also that of anti-CTLA4 þ DTIC (Figure 6b ). These data support the rationale that the in vivo antitumor effect of the combination of DTIC þ anti-CTLA4 relies on NK cell action. www.jidonline.org 503 DISCUSSION This paper reports the immunological properties of DTIC in the context of growing melanoma. We unraveled the capacity of DTIC to trigger NKG2D ligand expression on both murine and human tumor cells, resulting in augmented NK cell cytotoxic properties and IFNg production. This cytokine production is involved in the enhancement of MHC-I presentation of tumor-associated antigen and better CTL activity. In our in vivo model, the effect of DTIC on the immune system seems predominant, as its effect on tumor growth is lost in T cell-deficient nude mice, or in mice depleted of CD8 þ T cells, NK cells, or IFNg. Thus, DTIC can be added to the expanding list of chemotherapeutic agents whose antitumor effect depends, at least in part, on their capability to enhance the anticancer immune response (Zitvogel et al., 2008) .
Much evidence demonstrates that mouse and human NKG2D ligands are often expressed poorly on normal cells, but their expression levels are upregulated on tumor cells or virus-infected cells (Mistry and O'Callaghan, 2007) . NKG2D ligands are also expressed by melanoma cell lines and tumors (Casado et al., 2009; Paschen et al., 2009) . A given tumor cell line or primary tumor typically expresses one or more NKG2D ligands, although not usually all of them, suggesting a complexity in their regulation. Radiation (Kim et al., 2006; Gannage et al., 2008) and DNA-damaging agents (Fine et al., 2010) have demonstrated their capacity to upregulate NKG2D ligand expression. This regulation is mediated by the major DNA damage checkpoint pathway initiated by ATM (ataxia telangiectasia, mutated) or ATR (ATM-and Rad3-related) protein kinases (Soriani et al., 2009) . In this vein, we here report that DTIC is able to enhance expression of NKG2D ligand by mouse (Figure 3 ) and human (Figure 4 ) melanoma cell lines, favoring NK-driven killing and NKderived IFNg production. To our knowledge, this fact is previously unreported. The expression of NKG2D ligands in cells that do not express them endogenously renders the cells more prone to NK cell-mediated lysis in vitro, and reduces the tumorigenicity of tumor cell lines in vivo (Cerwenka et al., 2000 (Cerwenka et al., , 2001 Diefenbach et al., 2000 Diefenbach et al., , 2001 . Further research is, however, warranted to unravel the molecular mechanisms accounting for the enhanced NKG2D ligand expression on tumor cells following DTIC treatment.
The fact that DTIC treatment was ineffective in nude mice seems surprising, as DTIC is widely used as a cytotoxic drug for the treatment of melanoma. We propose that the NKG2D ligand modulation by the DTIC treatment may be sufficient to trigger an antitumor immune response, which strengthens this therapeutic effect. In previous studies, we also demonstrated that anthracyclines, oxaliplatine, and 5-fluorouracil antitumor effect was also dependent on an immune response (Apetoh et al., 2007; Ghiringhelli et al., 2009; Vincent et al., 2010) . It is conceivable that, in melanoma patients, NKG2D ligand upregulation triggers activation of immune effectors and enhances the efficacy of the treatment. Therefore, it could be relevant to check the NKG2D ligand expression in tumor cells before and after chemotherapy and perform a correlation analysis between NKG2D ligand expression and response to chemotherapy to corroborate this hypothesis.
DTIC effect was totally abrogated in NK-and IFNgdepleted mice, yet featured an early and transient effect in CD8 þ T cell-depleted mice (Figure 1c) , suggesting a sequential activation of these immune effectors following DTIC treatment. We propose that IFNg secretion establishes a key link between the activation of innate and adaptive immune effectors. Indeed, enhanced MHC-I expression by IFNg leads to higher accessibility of endogenous tumor antigens, processed and presented through peptide/MHC complexes on tumor cells, explaining the consequent vulnerability of melanoma cells to CTL. Furthermore, by augmenting the availability of antigens, DTIC enables the survival of lowavidity TCR clonotypes, easing epitode spreading (Palermo et al., 2010) , thereby favoring increased anticancer immunity and reduced tumor progression.
Specific stimulation of the host's immune system to induce melanoma tumor rejection has been attempted. Approaches to tumor-specific immunotherapy of melanoma have included chemoimmunotherapy combining IFN-a or IL-2 with In some conditions, anti-human NKG2D was added at a concentration of 10 mg ml
À1
. Viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The figure shows mean and SEM from three independent experiments. *Po0.05. DTIC therapy, the use of tumor lysates and whole tumor vaccines, tumor-derived peptides, DC-based vaccination protocols, and adoptive transfer of tumor-specific T cells (Kadison and Morton, 2003) . These approaches have so far obtained little success in the clinic, are complex and laborintensive, thereby limiting their potential for widespread use. However, the implementation of a new immunotherapy was recently approved by Food and Drug Administration for the treatment of unresectable or metastatic melanoma. Targeting immunosuppression by the anti-CTLA-4 antibody ipilimumab revealed a clinical benefit after failure of first-line chemotherapy (Hodi et al., 2010) . Recently, a new chemoimmunotherapy protocol with the association of ipilimumab and DTIC demonstrated superiority in terms of overall survival compared with DTIC administered alone (Robert et al., 2011) . However, it should be pointed out that the clinical advantage is only observed in a small percentage of patients and should therefore be balanced with the expansive cost of ipilimumab (about 100,800 dollar to treat one patient (Kaplan, 2011) ). Therefore, increasing our knowledge on the immunemediated effects of chemotherapy is an important step to optimize any immune-based regimen in melanoma. In this regard, our results showing that the combination of DTIC with anti-CTLA4 relies on NK cells hint us about the potential clinical relevance of our observation. Indeed, it is conceivable that some tumors may resist the DTIC-induced NKG2D ligand upregulation, and in these patients the immune effects of DTIC would be reduced or absent. Our results also point that CTLA4 blockade might be effective against tumor growth only in the presence of NK cells, which seems surprising and needs further investigations, according to the fact that CTLA4 inhibition is thought to only act through dampening of T-cell inhibition (Robert and Ghiringhelli, 2009; Tarhini and Iqbal, 2010) . To conclude, our results indicate that DTIC antitumor efficacy relies on NKG2D ligand expression by tumor cells, which results in NK cell activation and IFNg secretion, leading to increased tumor MHC-I presentation and higher CTL efficacy. We speculate that patients who feature upregulation of NKG2D ligands on tumor cells and NK cell activation after one cycle of DTIC may be better responders to immunomodulation and may be candidates in clinical trials that assess the efficacy of T cell-activating agents such as ipilimumab. As such, NKG2D ligand expression might be a predictive biomarker for DTIC treatment response; however, these data must first be validated in a clinical trial.
MATERIALS AND METHODS
Mice and cell lines B16F10 melanoma cells, syngeneic of C57BL/6, were obtained from the ATCC (Molsheim, France). B16F10 cells expressing OVA (B16OVA) were a kind gift from Laurence Zitvogel. MelC human melanoma cell line was a kind gift from Anne Caignard. Cells were cultured in RPMI 1640 (Lonza, Levallois Perret, France) with 10% fetal bovine serum enriched with 0.4 mM sodium pyruvate, 4 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), penicillin, streptomycin, and amphotericin B. C57BL/6 and Nude mice were purchased from the Centre d'élevage Janvier (Le Genest St Isle, France); OT-I were from Charles River (Saint Germain sur l'Arbresle, France) and were used at 6-10 weeks of age. Animals were all maintained according to the Animal Experimental Ethics Committee Guidelines.
Tumor model B16F10 cells (5 Â 10 5 in 100 ml PBS) were subcutaneously injected into the flank of mice. Mice were treated 7 days after tumor injection and received a unique intraperitoneal injection of DTIC at 100 mg kg À1 body weight.
Reagents
We used DTIC (Déticène; Sanofi Aventis, Paris, France) and doxorubicin (Pfizer, Paris, France 
Detection of calreticulin expression on tumor cells
B16F10 cancer cells were cultured for 24 hours in complete culture medium supplemented or not supplemented with DTIC (0.4. g l À1 ), doxorubicin (25 mM), or PBS. Cells were fixed with 1% paraformaldehyde, and then saturated with 200 ml of PBS supplemented with 30% fetal bovine serum before being stained with a rabbit anticalreticulin antibody (AbCam, Paris, France) for 20 minutes at 4 1C, followed by Cy5-conjugated anti-rabbit antibody (Amersham, GE Healthcare, Velizy-Villacoublay, France).
Quantitative PCR
Total RNA was extracted using TRIZOL (Invitrogen, Villebon sur Yvette, France) as recommended by the manufacturer. The RNAs were rehydrated and measured with a NanoDrop 1000 (ThermoScientific, Illkirch, France). Reverse transcription was performed using the kit ''M-MLV Reverse Transcriptase'' (Invitrogen) as recommended by the manufacturer. The samples were then placed in a Biometra (Archamps, France) thermocycler. The quantitative PCR reaction was performed using the kit ''SYBR Green PCR Master Mix'' (Applied Biosystems, Villebon sur Yvette, France) according to the manufacturer's recommendations, on an Applied 7500 device (Applied Biosystems). Relative messenger RNA levels were determined using the DCt method. Values were expressed relative to Actb. The sequences of the oligonucleotides used in this study are listed in the Table 1 .
NK cell cytotoxic assay B16F10 were cultured for 24 hours in complete culture medium supplemented or not supplemented with DTIC at 0.4 g l À1 . After 24 hours, B16F10 cells were harvested and incubated with increasing numbers of NK cells and IL-2 (1,000 UI ml
À1
). In some wells, NKG2D Fc was added at a concentration of 10 mg ml À1 . After 48 hours, cells were collected and B16F10 death was assessed using 4'-6-Diamidino-2-phenylindole staining by flow cytometry. NK cells were excluded as CD49b-positive events. For human experiments, peripheral blood mononuclear cells were isolated from healthy volunteers' blood, and NK cells were separated using the NK cell isolation kit (Miltenyi). NK cells were incubated overnight with melanoma target MelC, previously treated with PBS or DTIC. In some wells, antihuman NKG2D (BD biosciences) was added at a concentration of 10 mg ml À1 . Tumor cells were harvested and death was assayed using DAPI staining by flow cytometry or CellTiter assay (Promega, Lyon, France).
Determination of CD8
þ T-cell activation and cytotoxicity were subcutaneously injected into the thigh of C57BL/6 mice. Mice were treated or not treated with DTIC 7 days after injection. CD8 þ T cells from OT-I mice spleen and lymph nodes were isolated by magnetic selection, labeled by CFSE (10 mmol l À1 ), and then injected intravenously 8 days after tumor implantation. Some mice were treated with depleting anti-NK1.1 or anti-IFNg antibodies. Five days after injection of OT-I cells, mice were killed and tumordraining inguinal lymph node was removed. OT-I cell activation was assessed by CFSE dilution by flow cytometry.
Statistical analysis
Tests used were Student's t-test or Mann-Whitney test for the comparison of parametric and nonparametric means. For comparison of more than two groups, analysis of variance with Bonferroni post-test was used. All tests were performed with the GraphPad Prism software (La Jolla, CA). All P-values were two-tailed. A P-value of o0.05 was considered statistically significant for all experiments and is indicated with *.
